{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-100092","form_type":"8-K","ticker":"ACLS","cik":"0001113232","company_name":"AXCELIS TECHNOLOGIES INC","filed_at":"2021-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.192772+00:00","generated_at":"2026-06-29T22:21:06.020754+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Axcelis Q2 revenue $147.3M (beat), guides Q3 to $170M; FY2021 revenue >$625M","bullets":["Q2 revenue $147.3M, up 11% from Q1 $132.8M; first quarterly system revenue >$100M since 2004.","GAAP EPS $0.55 diluted, up from $0.48 in Q1; operating profit $24M.","Gross margin 43.5% vs 42.5% Q1; cash $220.5M; $13.4M stock repurchases.","Q3 guidance: revenue ~$170M, EPS ~$0.70, op profit ~$32M, gross margin ~42.5%.","Full-year 2021 revenue >$625M; strong demand for Purion implants in power devices."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-100092","json":"https://secwatch.observer/filing/0001104659-21-100092.json","markdown":"https://secwatch.observer/filing/0001104659-21-100092.md","text":"https://secwatch.observer/filing/0001104659-21-100092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1113232/000110465921100092/0001104659-21-100092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1113232/000110465921100092/tm2123731d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:21:06.020754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}